Asahi Kasei's $920M AiCuris Buy Leads to FDA OK | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling stories that highlight the dynamic nature of the industry, marked by strategic acquisitions, groundbreaking research, and significant regulatory milestones.

Starting with Asahi Kasei's acquisition of Bayer spinout AiCuris for a substantial $920 million, this investment has culminated in the FDA approval of a novel her...